Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer

BMC Cancer
F De FeliceV Tombolini

Abstract

Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to evaluate the role of OXP in this patient population. Literature searches were carried out in PubMed, Medline and Scopus databases. End points were overall survival (OS), disease free survival (DFS), local failure (LF) and distant failure (DF). Odd ratio (OR) with 95% confidence interval (CI) was calculated using random effects model. Four randomized trials were included. Patients treated with OXP-5FU CRT had significantly decreased DF (OR = 0.76; 95% CI, 0.60 to 0.97; p = 0.03) compared to standard CRT. OS, DFS and LF were not significantly different between groups. OXP significantly decreased DF, but does not improve OS e DFS compared to 5FU CRT. Precise role of OXP in neoadjuvant setting of LARC remains to be determined.

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Oct 22, 2004·The New England Journal of Medicine·Rolf SauerUNKNOWN German Rectal Cancer Study Group
Sep 15, 2006·The New England Journal of Medicine·Jean-François BossetUNKNOWN EORTC Radiotherapy Group Trial 22921
Jun 7, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Vincenzo ValentiniChristine Verfaillie
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre GérardThierry Conroy
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlo AscheleLuca Boni
Jan 24, 2012·Journal of the National Cancer Institute·Hanna K SanoffDeborah Schrag
Sep 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollA Cervantes
Oct 16, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Xin AnPei-Rong Ding
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J O'ConnellNorman Wolmark
Dec 3, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Aldo SainatoLuca Cionini
May 21, 2015·American Society of Clinical Oncology Educational Book·Martin R WeiserDeborah Schrag

❮ Previous
Next ❯

Citations

Aug 23, 2019·The British Journal of Surgery·S NougaretUNKNOWN GRECCAR Study Group
Jan 14, 2020·Current Treatment Options in Oncology·Francesca De FeliceVincenzo Tombolini
Jan 31, 2019·Annals of Gastroenterological Surgery·Kimihiro YamashitaYoshihiro Kakeji
Dec 1, 2019·Journal of Cancer Research and Clinical Oncology·Francesca De FeliceV Tombolini
Aug 20, 2019·Future Oncology·Lucy GatelyPeter Gibbs
Feb 24, 2021·Translational Oncology·Francesca De FeliceEnrico Cortesi

❮ Previous
Next ❯

Software Mentioned

Scopus
Review Manager

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.